Condelli Valentina, Calice Giovanni, Cassano Alessandra, Basso Michele, Rodriquenz Maria Grazia, Zupa Angela, Maddalena Francesca, Crispo Fabiana, Pietrafesa Michele, Aieta Michele, Sgambato Alessandro, Tortora Giampaolo, Zoppoli Pietro, Landriscina Matteo
Laboratory of Preclinical and Translational Research, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), 85028 Potenza, Italy.
Medical Oncology Unit, Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Cancers (Basel). 2021 Jan 5;13(1):158. doi: 10.3390/cancers13010158.
Epigenetics is involved in tumor progression and drug resistance in human colorectal carcinoma (CRC). This study addressed the hypothesis that the DNA methylation profiling may predict the clinical behavior of metastatic CRCs (mCRCs). The global methylation profile of two human mCRC subgroups with significantly different outcome was analyzed and compared with gene expression and methylation data from The Cancer Genome Atlas COlon ADenocarcinoma (TCGA COAD) and the NCBI GENE expression Omnibus repository (GEO) GSE48684 mCRCs datasets to identify a prognostic signature of functionally methylated genes. A novel epigenetic signature of eight hypermethylated genes was characterized that was able to identify mCRCs with poor prognosis, which had a CpG-island methylator phenotype (CIMP)-high and microsatellite instability (MSI)-like phenotype. Interestingly, methylation events were enriched in genes located on the q-arm of chromosomes 13 and 20, two chromosomal regions with gain/loss alterations associated with adenoma-to-carcinoma progression. Finally, the expression of the eight-genes signature and MSI-enriching genes was confirmed in oxaliplatin- and irinotecan-resistant CRC cell lines. These data reveal that the hypermethylation of specific genes may provide prognostic information that is able to identify a subgroup of mCRCs with poor prognosis.
表观遗传学参与人类结直肠癌(CRC)的肿瘤进展和耐药性。本研究探讨了DNA甲基化谱可能预测转移性结直肠癌(mCRC)临床行为的假说。分析了两个预后显著不同的人类mCRC亚组的整体甲基化谱,并与来自癌症基因组图谱结肠腺癌(TCGA COAD)以及NCBI基因表达综合数据库(GEO)GSE48684 mCRC数据集的基因表达和甲基化数据进行比较,以确定功能甲基化基因的预后特征。鉴定出了一个由八个高甲基化基因组成的新的表观遗传特征,该特征能够识别预后不良的mCRC,这些mCRC具有CpG岛甲基化表型(CIMP)高和微卫星不稳定性(MSI)样表型。有趣的是,甲基化事件在位于13号和20号染色体q臂上的基因中富集,这两个染色体区域的增减改变与腺瘤到癌的进展相关。最后,在奥沙利铂和伊立替康耐药的CRC细胞系中证实了这八个基因特征和MSI富集基因的表达。这些数据表明,特定基因的高甲基化可能提供预后信息,能够识别出预后不良的mCRC亚组。